Oligonucleotide Therapeutics Market

The oligonucleotide therapeutics market is projected to reach USD 17.70 billion by 2030, from USD 7.19 billion in 2025, with a CAGR of 19.7%. This growth is mainly driven by strong support from governments and public institutions for genomics, precision medicine, and rare disease care. This funding enhances genetic testing, patient identification, and referral pathways. As a result, it increases the number of patients treated with approved oligo drugs.

The oligonucleotide therapeutics market is consolidated. Major players in the market include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US), among others.

To know about the assumptions considered for the study download the pdf brochure

Biogen is a prominent player in the oligonucleotide therapeutics market. The company has a strong foundation in antisense (ASO) medicines, which maintains steady demand for clinical and commercial-grade oligonucleotide drug substances. Its marketed ASO products, such as SPINRAZA (nusinersen) and QALSODY (tofersen), generate recurring manufacturing cycles supported by repeat dosing and long-term patient management.

Alnylam Pharmaceuticals, Inc. is a major driver of demand in the oligonucleotide therapeutics market. The company's portfolio focuses on RNAi (siRNA) medicines, which sustain steady demand for clinical and commercial-grade oligonucleotide drug substances. Its marketed products (e.g., AMVUTTRA, GIVLAARI, and OXLUMO) support repeat manufacturing cycles as patient access increases.

Sarepta Therapeutics, Inc. is a key player in the oligonucleotide therapeutics market, mainly because of its exon-skipping products for treating Duchenne muscular dystrophy. Its approved products include EXONDYS 51, VYONDYS 53, and AMONDYS 45, all of which are antisense oligonucleotides.

Market Ranking

The oligonucleotide therapeutics market is consolidated. Growth is driven mainly by ASO and siRNA drugs that require high-value, GMP-grade oligo drug substances. As programs move from clinical to commercial phases, buyers are increasing their requirements for sequence accuracy, impurity control, and regulatory-grade documentation. These factors lead to higher costs for complex synthesis, purification, and advanced analytical release testing. As a result, therapeutic supply now represents the largest value pool.

Related Reports:

Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com